Stockscreener 앱 받기
2.17
1.81%
-0.04
전일 마감가:
$2.21
열려 있는:
$2.19
하루 거래량:
2.05M
Relative Volume:
0.80
시가총액:
$312.44M
수익:
$288.95M
순이익/손실:
$-119.03M
주가수익비율:
-2.4098
EPS:
-0.9005
순현금흐름:
$60.67M
1주 성능:
-8.44%
1개월 성능:
+2.36%
6개월 성능:
-57.37%
1년 성능:
-74.80%
1일 변동 폭
$2.135
$2.26
1주일 범위
$2.10
$2.35
52주 변동 폭
$1.665
$10.03
마라바이 라이프 Stock (MRVI) Company Profile
명칭
Maravai Lifesciences Holdings Inc
전화
(858) 546-0004
주소
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
MRVI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
2.17 | 341.22M | 288.95M | -119.03M | 60.67M | -0.9005 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
마라바이 라이프 Stock (MRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | 개시 | Guggenheim | Neutral |
| 2024-12-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-08 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | 개시 | Craig Hallum | Buy |
| 2023-12-12 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-08-08 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-01-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-11-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2020-12-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 개시 | Credit Suisse | Outperform |
| 2020-12-15 | 개시 | Goldman | Buy |
| 2020-12-15 | 개시 | Jefferies | Buy |
| 2020-12-15 | 개시 | Robert W. Baird | Outperform |
| 2020-12-15 | 개시 | Stifel | Buy |
| 2020-12-15 | 개시 | William Blair | Outperform |
| 2020-12-14 | 개시 | UBS | Buy |
모두보기
마라바이 라이프 주식(MRVI)의 최신 뉴스
Quantoom Biosciences and TriLink BioTechnologies Sign a Supply and License Agreement - Insider Monkey
TriLink and Quantoom partner to expand global vaccine access By Investing.com - Investing.com South Africa
MRVI: TriLink BioTechnologies Partners with Quantoom for Enhanced mRNA Production | MRVI Stock News - GuruFocus
TriLink and Quantoom partner to expand global vaccine access - Investing.com Australia
Maravai's TriLink, Quantoom Sign License, Supply Agreement - marketscreener.com
Leading COVID-19 Vaccine Technology CleanCap Expands Global Access Through Quantoom Partnership - Stock Titan
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Holdings Cut by Bank of America Corp DE - Defense World
ProShare Advisors LLC Raises Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences Announces Shareholder Meeting Results - Investing.com Australia
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI) - Defense World
Maravai Lifesciences Holds Annual Shareholders Meeting - TipRanks
Maravai LifeSciences Announces Shareholder Meeting Results By Investing.com - Investing.com Canada
BNP Paribas Financial Markets Purchases Shares of 66,443 Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
CORRECTION -- Maravai LifeSciences Releases 2024 Sustainability Report | MRVI Stock News - GuruFocus
Maravai LifeSciences Releases 2024 Sustainability Report Highlighting Product Innovation, Governance Enhancements, and Commitment to Sustainable Growth - Nasdaq
CORRECTIONMaravai LifeSciences Releases 2024 Sustainability Report - The Manila Times
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report - GlobeNewswire
Maravai Sustainability Report: 10x Manufacturing Expansion Plus Major Green Energy Milestones - Stock Titan
Maravai LifeSciences Releases 2024 Sustainability Report - GlobeNewswire
Maravai LifeSciencesReleases 2024 Sustainability Report - The Manila Times
Maravai LifeSciences Sustainability Report: 49 New Products and 10X GMP Manufacturing Expansion Drive Growth - Stock Titan
Northern Trust Corp Buys 53,474 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Revolutionary mRNA Synthesis Kit Achieves 2X Yield, 85% Lower dsRNA: TriLink's Game-Changing Launch - Stock Titan
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Maravai LifeSciences Q1 2025 Earnings Call: Growth Amid Challenges - TipRanks
Price T Rowe Associates Inc. MD Acquires 7,946 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Robert W. Baird Has Lowered Expectations for Maravai LifeSciences (NASDAQ:MRVI) Stock Price - Defense World
Stock Traders Buy Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI) - Defense World
TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines - marketscreener.com
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q1 Loss, Tops Revenue Estimates - MSN
RBC Capital Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI) - The Globe and Mail
Major mRNA Vaccine Breakthrough: TriLink and IVI Join Forces to Transform Global Vaccine Access - Stock Titan
Maravai (MRVI) Offers 2025 Revenue Outlook Excluding Key Factors - GuruFocus
MRVI: Analyst Firm Lowers Price Target for Maravai LifeSciences - GuruFocus
These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Maravai LifeSciences (MRVI) Exceeds Q1 Revenue Expectations | MR - GuruFocus
Maravai (MRVI) Offers 2025 Revenue Outlook Excluding Key Factors | MRVI Stock News - GuruFocus
Maravai Lifesciences (MRVI) Price Target Reduced by Baird Analys - GuruFocus
Assessing Maravai LifeSciences: Insights From 5 Financial Analysts - Benzinga
Maravai LifeSciences (MRVI) Target Price Lowered by Baird | MRVI Stock News - GuruFocus
MRVI: Analyst Reduces Price Target but Maintains Buy Rating on M - GuruFocus
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2025 Earnings Call Transcript - Insider Monkey
Maravai Lifesciences (MRVI) Price Target Reduced by Baird Analyst | MRVI Stock News - GuruFocus
Maravai LifeSciences Holdings Inc (MRVI) Q1 2025 Earnings Call Highlights: Navigating Growth ... - Yahoo Finance
MRVI: Analyst Firm Lowers Price Target for Maravai LifeSciences | MRVI Stock News - GuruFocus
Maravai LifeSciences Holdings Inc (MRVI) Q1 2025 Earnings Call H - GuruFocus
Maravai LifeSciences Holdings, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:MRVI) - Seeking Alpha
Earnings call transcript: Maravai Lifesciences Q1 2025 sees revenue beat, stock up - Investing.com
마라바이 라이프 (MRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
1.24%
자본화:
|
볼륨(24시간):